Palo Alto Investors LP Travere Therapeutics, Inc. Transaction History
Palo Alto Investors LP
- $856 Million
- Q1 2024
A detailed history of Palo Alto Investors LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Palo Alto Investors LP holds 110,719 shares of TVTX stock, worth $910,110. This represents 0.1% of its overall portfolio holdings.
Number of Shares
110,719
Previous 110,719
-0.0%
Holding current value
$910,110
Previous $995,000
14.27%
% of portfolio
0.1%
Previous 0.09%
Shares
3 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.5MCall Options Held
66.9KPut Options Held
265K-
Black Rock Inc. New York, NY7.8MShares$64.1 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$61.7 Million0.79% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$60.6 Million1.88% of portfolio
-
State Street Corp Boston, MA6.61MShares$54.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$51.5 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $528M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...